Cerillion (CER)

Cerillion (CER) is a leading provider of charging, billing, and customer management systems with more than 20 years’ experience delivering its solutions across a broad range of industries. 

Henderson Smaller Companies Investment Trust (HSL)

Henderson Smaller Companies Investment Trust (HSL) aims to maximise shareholders’ total returns (capital and income) by investing in smaller companies that are quoted in the United Kingdom. We do this by following a disciplined process of investment in a diversified portfolio of companies which benefit from sustainable growth trends, and by controlling costs and using borrowings to enhance returns.

STV Group (STVG)

STV Group plc is Scotland’s home of news, entertainment and drama, providing audiences with top-quality programming on air, online and on demand.

STV is the most popular peak time TV channel in Scotland, reaching 3 million viewers each month.  Fast-growing free streaming service, STV Player, is available on all major platforms offering UK viewers an extensive catalogue of content.  Award-winning production group STV Studios makes shows for broadcasters and streamers including prison drama Screw, police drama Blue Lights and quiz format Bridge of Lies.

VolitionRx (VNRX)

VolitionRX is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.

As cancer screening programs become more widespread, VolitionRX products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.

VolitionRX research and development activities are currently centered in Belgium, with additional offices in London, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.